COMMUNIQUÉS West-GlobeNewswire

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
22/04/2026
Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to support initiation of [...]
Neurona Presents Updated Data from Ongoing Clinical Trials of Rezanecel (NRTX-1001) Regenerative Cell Therapy in Mesial Temporal Lobe Epilepsy at 2026 American Academy of Neurology (AAN) Annual Meeting
22/04/2026
- UNILATERAL MTLE: Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy evaluation period (N=9), and 100% median disabling seizure reduction in [...]
Humacyte Appoints Jim Mercadante as Chief Commercial Officer
22/04/2026
– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success in vascular and [...]
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
22/04/2026
NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that updated [...]
MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
22/04/2026
MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March [...]
Repligen to Report First Quarter 2026 Financial Results
22/04/2026
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first [...]
Kestra Showcases Accelerated Innovation at HRS 2026
22/04/2026
KIRKLAND, Wash., April 22, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it will exhibit at Heart Rhythm [...]
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
22/04/2026
ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab [...]
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
22/04/2026
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible Findings also correlate with previously [...]
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
22/04/2026
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple [...]
Glyco Harmony Drops Examined - 2026 Consumer-Focused Report on Ingredients, Claims & Label Insights
22/04/2026
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Glyco Harmony Drops has been gaining attention among people looking for natural ways to support blood sugar balance without relying solely on traditional approaches. As [...]
Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program
22/04/2026
PARIS, France – 22 April 2026 : Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deliver two poster [...]
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
22/04/2026
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today [...]
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
22/04/2026
Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitor Atopic dermatitis [...]
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
22/04/2026
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previously reported [...]
Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026
22/04/2026
MKIs uniquely block multiple receptor tyrosine kinases (RTKs) simultaneously, addressing the inflammatory, vascular, and fibrotic causes of serious, underserved front-of-the-eye diseases Lead MKI candidates, CBT-001 and [...]
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
22/04/2026
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of Hematology (ASH) Annual [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22/04/2026
PALO ALTO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Stereotaxis Announces First MAGiC Procedures in the United States
22/04/2026
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US [...]

Pages